Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer

BACKGROUND: Small-molecule tyrosine inhibitor anlotinib which developed in China has been approved as a third-line treatment for patients with small-cell lung cancer (SCLC). Our previous clinical study found that anlotinib combined with S-1 has better short-term ORR than the single-agent anlotinib o...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Xinhang, Pi, Wenhu, Lan, Yanli, Wu, Xiaomai, Lv, Dongqing, Meng, Yinnan, Yang, Haihua, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225918/
https://www.ncbi.nlm.nih.gov/pubmed/35757014
http://dx.doi.org/10.1155/2022/4484211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225918/
https://www.ncbi.nlm.nih.gov/pubmed/35757014
http://dx.doi.org/10.1155/2022/4484211

Ejemplares similares